Previous

Collaborations Pharmaceuticals, Inc. demonstrates a treatment for CLN1 Batten disease crosses the blood-brain-barrier
Next

Collaborations Pharmaceuticals and UTMB awarded a $1,999,195 contract for Pyronaridine as an oral Treatment for Ebola